Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients
Paolo Carlini(National Cancer Institute), Francesco Cognetti(Apple (Israel)), Michèle Milella(National Cancer Institute), Emilio Bria(Università Cattolica del Sacro Cuore), Alessandra Fabi(Agostino Gemelli University Polyclinic), Enzo Maria Ruggeri, Nello Salesi(Tumori Foundation), Nicola Cresti(Ospedale Santa Chiara), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Alimonti(Veneto Institute of Molecular Medicine), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Andrea Michelotti(University of Pisa), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Sergio Ricci(St Bartholomew's Hospital), Manuela Pellegrini(APR (Italy))
Cited by 36
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Cellular Senescence: Aging, Cancer, and Injury
|Physiological Reviews|2019|1.3k